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Abstract
Background Management of proctitis refractory to conventional therapies presents a common clinical problem. The use 
of acetarsol suppositories, which are derived from organic arsenic, was first described in 1965. Data concerning clinical 
efficacy and tolerability are very limited.
Aim To examine the efficacy of acetarsol suppositories for the treatment of refractory proctitis.
Methods A retrospective analysis was performed on patients with inflammatory bowel disease treated with acetarsol sup-
positories between 2008 and 2014 at Addenbrooke’s Hospital, Cambridge, United Kingdom. Clinical response was defined 
as resolution of symptoms back to baseline at the time of next clinic review.
Results Thirty-nine patients were prescribed acetarsol suppositories between March 2008 and July 2014 (29 patients with 
ulcerative colitis, nine with Crohn’s disease, and one with indeterminate colitis). Thirty-eight were included for analysis. 
The standard dose of acetarsol was 250 mg twice daily per rectum for 4 weeks. Clinical response was observed in 26 patients 
(68%). Of the 11 patients who had endoscopic assessment before and after treatment, nine (82%) showed endoscopic improve-
ment and five (45%) were in complete remission (Wilcoxon signed-rank test p = 0.006). One patient developed a macular 
skin rash 1 week after commencing acetarsol, which resolved within 4 weeks of drug cessation.
Conclusion Acetarsol was effective for two out of every three patients with refractory proctitis. This cohort had failed a 
broad range of topical and systemic treatments, including anti-TNFα therapy. Clinical efficacy was reflected in significant 
endoscopic improvement. Adverse effects of acetarsol were rare.
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Introduction
Acetarsol suppositories are derived from organic arsenic, 
meaning that the arsenic atom is linked to carbon. Arsenic 
was first described as a treatment for proctitis in 1965 [1]. 
The mechanism of action is unknown. Data concerning clin-
ical efficacy and tolerability of acetarsol suppositories are 
limited to two small studies (Connell et al. [1], 44 patients; 
Forbes et al. [2], ten patients). Acetarsol does have an anti-
microbial effect and is been used for decades in the treatment 
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of refractory bacterial vaginosis [3]. In refractory proctitis, 
the usual dose of acetarsol suppositories is 250 mg BD for 
4 weeks, with at least a 4-week washout period prior to a 
second course, if this is required. Acetarsol is not currently 
approved by the FDA for use in the USA.
Here, we report our experience of using acetarsol sup-
positories in the management of 39 patients with refractory 
proctitis. Almost half of patients with ulcerative colitis have 
inflammation confined to the rectum [4], and in those with 
more extensive disease, rectal inflammation may contrib-
ute disproportionately to the burden of symptoms. Trials 
using conventional 5-aminosalicylic acid agents (5-ASAs) 
to treat proctitis have demonstrated these to be effective in 
78–87% of patients [5, 6]; however, a significant minority 
do not respond—and indeed a hard core of such patients 
also appear resistant to both thiopurine therapy and biologic 
therapy [7, 8].
Methods
A retrospective analysis was performed on patients with IBD 
who were prescribed acetarsol suppositories between 2008 
and 2014 at Addenbrooke’s Hospital, Cambridge, United 
Kingdom. Patients were identified through the hospital phar-
macy database. All patients who received acetarsol supposi-
tories during this period were included. This included some 
patients who had more extensive disease than that confined 
to the rectum, but where the rectum was the maximally 
inflamed segment. When available, endoscopic data were 
collected. This was performed at the discretion of the clini-
cian and consisted of either flexible sigmoidoscopy or rigid 
sigmoidoscopy. Mayo endoscopic sub-scores were deter-
mined retrospectively; these were based on endoscopic pho-
tos and written descriptions provided in the medical record. 
Clinical response was determined as an improvement in 
symptoms or reduction in the Mayo endoscopic sub-score 
by one or more point. Clinical remission was defined as 
symptoms (rectal bleeding, tenesmus, and urgency return-
ing) to “normal” and/or an endoscopic sub-score of one or 
zero. Serum arsenic levels were not routinely measured. 
This study was conducted with the approval of the Human 
Research and Ethics Committee of Cambridge University 
Hospitals NHS Foundation Trust.
Statistics
Statistical analysis was performed using SPSS version 24 
(IBM) and R [9]. P values less than 0.05 were considered 
significant. Correction for multiple comparison was made 
using the Benjamini and Hochberg method using the stats 
package in R.
Results
Thirty-nine patients received acetarsol suppositories during 
the study period (29 UC, nine Crohn’s disease, one indeter-
minate colitis). One patient who was treated for pouchitis 
was excluded from the analysis.
Patient Characteristics
Demographic and prior treatment details are shown in 
Table 1. The first course of acetarsol was given, on average, 
7 years following the initial diagnosis of IBD. Only patients 
with refractory disease were prescribed acetarsol; on aver-
age, they had failed medications from three different classes 
[mean 3.0, ± standard deviation (SD) 0.93]. The median 
duration for follow-up was 6.5 years ± SD 3.4 following the 
first use of acetarsol. Four patients were receiving anti-TNFα 
therapy at the time of the course of acetarsol, 21 (55%) were 
receiving thiopurines, seven (18%) were on methotrexate, 
and seven patients (18%) were prescribed concurrent cor-
ticosteroids (high-dose oral corticosteroids in four patients, 
while three were maintained on long-term low-dose corti-
costeroid regimens).
Clinical response was observed in 26 patients (68%). 
Of the 11 patients who had endoscopic assessment before 
and after treatment (Fig.  1), nine showed endoscopic 
improvement and four were in complete remission (Mayo 
endoscopic sub-score = 0, Wilcoxon signed-rank sum test 
p = 0.006). The only clinical parameter that correlated 
with clinical response was the number of previously failed 
Table 1  Baseline characteristics of the patient cohort
Total
Number of patients 38
Median age [years (± standard deviation)] 39.3 (± 15)
Sex
 Male 16 (42%)
 Female 22 (58%)
Ulcerative colitis 29 (76%)
Crohn’s disease 9 (24%)
Median duration of disease (years) 6.9 (± 5.0)
Median follow-up (years) 6.4 (± 3.4)
Prior treatment
 5-ASA (oral) 29 (76%)
 5-ASA (topical) 38 (100%)
 Corticosteroids (systemic) 36 (95%)
 Corticosteroids (topical) 34 (90%)
 Thiopurines 31 (82%)
 Methotrexate 13 (34%)
 Anti-TNF agents 9 (24%)
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immunomodulators (p = 0.01, mean 1.35 in responders 
and 2.46 in non-responders). Otherwise, there were no 
significant associations with response to treatment with 
respect to gender, IBD subtype, disease extent limited 
to the rectum, the presence of perianal fistula, previ-
ous failed medications use or concurrent medications 
(including corticosteroid, 5-ASAs, thiopurine and anti-
TNFα drugs) after correction for multiple testing. Initial 
serum C-reactive protein (CRP) levels were not higher in 
responders compared with non-responders (mean CRP 
12.5 mg/L vs. 10.5, respectively, p = 0.85).
Six patients (16%) with extensive disease underwent 
colectomy during the follow-up period, including two 
patients who had initially responded to acetarsol. Six 
patients required escalation of therapy: two went on to 
receive anti-TNFα therapy, two were enrolled in a clinical 
trial, one patient was commenced on tacrolimus enemas, 
and one responded to subsequent treatment with metho-
trexate. No patients in our cohort developed renal, cardiac 
or neurological disease during the follow-up period nor 
were any malignancies diagnosed.
One patient developed a moderate macular skin rash 
1 week after commencing acetarsol suppositories. Treat-
ment was stopped immediately and the rash resolved 
within 4  weeks. Skin biopsy confirmed superficial 
perivascular dermatitis, consistent with a drug rash.
Discussion
In this paper, we describe the experience of a single ter-
tiary referral center in the United Kingdom, where acetar-
sol suppositories have been used for the treatment of 
refractory symptoms of proctitis since 2004. Arsenic, a 
metalloid element that exists in both organic and inor-
ganic forms, has been used in medicine and other indus-
tries for over 2400 years [10]. Acetarsol is formulated 
from organic arsenic, meaning that the arsenic atom is 
attached to hydrocarbon complexes. Organic arsenic is 
far less toxic than the inorganic form [11] and is com-
monly found in seafood [12]. Following consumption of 
lobster, for example, high levels of organic arsenic are 
measurable in urine [13]. In vitro testing has demonstrated 
organic arsenic compounds to be 50–600 times less toxic 
than inorganic arsenic compounds [14]. Exposure to inor-
ganic arsenic, however, can lead to severe gastrointestinal, 
neurological and renal damage, and even death through 
cardiac arrhythmia [15]. Additionally, chronic exposure 
to inorganic arsenic, for example through contaminated 
groundwater or crops, is associated with skin lesions and 
an increased risk of certain malignancies (skin, bladder, 
and lung).
The mode of action of acetarsol is unclear. Conversely, 
more is known about inorganic arsenic, especially its 
potential anti-inflammatory and carcinogenic effects. 
miRNAs may play a role in the anti-inflammatory effects 
of arsenic and may have been implied in its carcinogenic 
potential [16–18], with reports linking it to urothelial and 
skin cancers among others. Inorganic arsenic is a potent 
inducer of MAP kinase signal transduction pathways. The 
differential activation of MAP kinase pathways may con-
tribute to cell growth regulation and cell death in response 
to diverse doses of arsenic with high inorganic concentra-
tion leading to apoptosis and low concentrations resulting 
in enhanced cell proliferation and carcinogenesis [17]. 
Given that such significant toxicities have not been associ-
ated with organic arsenic, it is probable that its biological 
properties differ to those of inorganic arsenic.
In our clinical experience, patients respond quite rap-
idly to acetarsol suppositories, often within a matter of 
a few days. The response is sometimes temporary, and 
patients may require further courses of treatment. Even 
after relapse, patients usually responded to a second 
course. Of our cohort, six patients (15%) had multiple 
courses of acetarsol—up to four courses in total. All 
of these patients achieved a clinical response with the 
subsequent courses. It has been our practice to observe 
a 4-week “washout” period prior to a second course to 
avoid systemic arsenic exposure. However, we do not rou-
tinely measure serum arsenic levels. In their 1989 paper, 
Fig. 1  Pre-treatment and post-treatment Mayo endoscopic sub-scores 
following treatment with acetarsol suppositories
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Forbes et al. did measure serum and urine arsenic levels 
and demonstrated serum concentration approaching the 
toxic range (> 200 µg/L) during the first week of treatment 
in most patients. Serum levels decreased rapidly despite 
ongoing treatment. This probably reflects a reduction in 
systemic absorption of acetarsol as rectal inflammation 
decreases. Serum arsenic levels returned to baseline lev-
els in all patients 4 weeks after treatment cessation. Our 
study was not designed to assess the safety of acetarsol. 
However, no patients in our cohort developed conditions 
consistent with arsenic toxicity in the follow-up period 
(mean 6.5 years). Nevertheless, as this was a retrospective 
analysis of medical records at a single institution, condi-
tions diagnosed and treated elsewhere may have not been 
recorded. Acetarsol suppositories were well tolerated by 
our cohort, with only one patient experiencing an adverse 
reaction. This patient developed a moderate skin rash that 
settled promptly following drug withdrawal.
In 1965, Connell et al. published a double-blind study 
of 44 patients with proctitis [1]. The patients were rand-
omized to receive two 5 mg prednisolone suppositories or 
two 250 mg acetarsol suppositories, nightly for 3 weeks. 
Twenty patients in each group were followed up and under-
went sigmoidoscopy. Endoscopic improvement was seen in 
19 patients in the acetarsol group, versus 17 in the predni-
solone group. Symptomatic improvement was noted in 18 
patients in the acetarsol group versus 15 of those treated 
with prednisolone. One patient in the acetarsol group expe-
rienced jaundice 2 weeks into treatment, which settled upon 
drug withdrawal. It should be noted that these patients were 
not a group refractory to other treatments and therefore rep-
resent a different cohort to our patients.
In our cohort, endoscopic evaluation was undertaken 
before and after treatment in 11 patients (Fig. 1). All four 
patients who were in endoscopic remission after the course 
of acetarsol suppositories (which we defined as a Mayo 
endoscopic sub-score of zero) had also achieved a clinical 
response. A further four patients had a post-treatment Mayo 
endoscopic sub-score of one, indicating only mild endo-
scopic disease. Similarly, all of these patients had achieved 
a clinical response.
Arsenic has similar chemical properties to bismuth, which 
is also a heavy metal used in the treatment of proctitis [19]. 
In a randomized double-blinded study of 63 patients with 
distal colitis, participants received either nightly enemas 
comprising of 5-ASA (2 g in 100 mL) or bismuth citrate car-
bomer (equivalent to 450 mg bismuth citrate) for 4 weeks. 
Clinical remission was observed in 18 of 32 patients in the 
5-ASA group and 12 of 31 patients in the bismuth group 
(p = 0.16).
This study represents the largest cohort of patients treated 
with acetarsol suppositories reported to date and the first 
publication on this topic in over 25 years. We recognize the 
significant limitations of a retrospective analysis such as 
this. Formal Mayo scores, including sub-scores for rectal 
bleeding, stool frequency, and physician’s global assessment, 
were not possible due to the nature of the medical records. 
Thus, subjective definitions of clinical response and remis-
sion were used. However, we were able to objectively assign 
endoscopic Mayo sub-scores to a proportion of our patients. 
Not all patients underwent endoscopic evaluation in a timely 
manner following treatment; in fact, only 11 of 38 patients 
had a follow-up endoscopy at all, and this was performed 
at the discretion of the treating physician. The median time 
from the end of the treatment course until endoscopic evalu-
ation was 5 months, raising doubt about the significance of 
the endoscopic findings. Patients who did undergo repeat 
endoscopy did so at the time of routine clinic visit, rather 
than in a protocolled manner to investigate the efficacy 
of acetarsol. Our cohort was typical of those with refrac-
tory proctitis. They had been affected by IBD for median 
6.9 years (SD ± 5.0) and had tried a median 5.5 ± 1.2 differ-
ent medications prior to the course of acetarsol. One quarter 
of our cohort had previously been treated with anti-TNFα 
therapy, and 82% had received prior thiopurine therapy.
In conclusion, acetarsol was effective in two out of 
every three patients with refractory proctitis. Our cohort 
had previously failed a broad range of topical and systemic 
treatments. The clinical efficacy reflected the significant 
endoscopic improvements. Adverse effects of acetarsol 
were rare. Further evidence, in the form of a prospective 
clinical trial, is required before recommending wider use 
of acetarsol for the treatment of refractory proctitis.
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